转移性去势抵抗性前列腺癌抗体靶点表达模式
研究分析296例mCRPC活检中62个抗体可靶向蛋白的基因表达,发现KLK2、FOLH1(PSMA)和STEAP1中位表达最高,靶点表达与转录组亚型相关而与基因组分类无关,CD46在缺乏已知靶点表达的预后不良亚组中高表达。
要点
- 靶点表达与转录组亚型相关,与HRD、MSI等基因组分类无关
- CRPC-AR与CRPC-SCL亚型多种靶点表达最高,CRPC-WNT普遍偏低
- CD46在CRPC-NE及缺乏KLK2/FOLH1/STEAP1表达的肿瘤中高表达
核心结论
- 多个抗体靶点在mCRPC中广泛表达,但表达随转录组亚型而异。
- CRPC-WNT等亚型表达靶点较少,提示需替代治疗策略。
- CD46在多种亚型中广泛表达,包括临床棘手的CRPC-NE及缺乏 established 靶点表达的肿瘤。
研究设计与样本
- 回顾性分析296例mCRPC活检中62个抗体可靶向蛋白的基因表达。
- 评估靶点表达与基因组分类及转录组亚型的关联。
- 在独立队列和单细胞转录组学中验证亚组特异性靶点。
主要发现
- KLK2、FOLH1(PSMA)和STEAP1的中位表达在全队列最高。
- 靶点表达与同源重组缺陷、微卫星不稳定、CDK12、TP53、PTEN或AR改变等基因组分类无关。
- CRPC-AR与CRPC-SCL亚型多种靶点表达最高,包括KLK2、FOLH1和SLC44A4。
- CRPC-NE表达异质,CD46表达高;CRPC-WNT总体靶点表达低。
- CD46在KLK2、FOLH1和STEAP1低表达的预后不良亚组中高表达。
临床怎么用
- 抗体药物治疗选择可参考转录组亚型而非仅基因组分类。
- 对CRPC-WNT等低表达亚型应考虑替代治疗策略。
- CD46可作为CRPC-NE及缺乏 established 靶点表达者的候选靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Survival in metastatic castration-resistant prostate cancer (mCRPC) patients remains limited and treatment is complicated by tumor heterogeneity. As antibody-based therapeutics emerge, identifying actionable antigen targets and patient subgroups most likely to benefit is essential. MATERIALS & METHODS: Gene expression of 62 antibody-targetable proteins was analyzed in 296 mCRPC biopsies. These genes encode proteins targeted by approved or investigational antibody-based cancer therapeutics. Associations between target expression with genomic classifications and transcriptomic subtypes were evaluated. Target expression was also assessed in tumors with low expression of established mCRPC targets. Subgroup-specific targets were validated in an independent cohort and single-cell transcriptomics. RESULTS: Established targets KLK2, FOLH1 (PSMA) and STEAP1 showed the highest median expression across the cohort. Target expression did not correlate with genomic classifications, including homologous recombination deficiency, microsatellite instability, CDK12, TP53, PTEN or AR alterations Target expression did associate with transcriptomic subtypes: CRPC-AR (driven by androgen receptor-signaling) and CRPC-SCL (stem cell-like features, AP-1/YAP/TAZ-driven), displayed the highest expression of multiple targets, including KLK2, FOLH1, and SLC44A4. CRPC-NE (neuroendocrine phenotype) showed heterogeneous expression, with high CD46 expression, whereas CRPC-WNT (Wnt-signaling driven) generally showed low target expression. Notably, CD46 was highly expressed in tumors with low KLK2, FOLH1, and STEAP1 expression, a subgroup associated with poor prognosis. CONCLUSIONS: Although several antibody targets showed broad expression in mCRPC-tumors, expression varied by transcriptomic subtype. Subgroups such as CRPC-WNT expressed fewer targets, suggesting the need for alternative therapeutic strategies. CD46 emerged as a promising target, with wide expression across multiple subtypes, including clinically challenging CRPC-NE and mCRPC tumors lacking expression of established targets.
引用
- van Dijk TC, Smid M, Robbrecht DGJ, et al. Expression patterns of potential targets for antibody-directed therapy in metastatic castration-resistant prostate cancer patients. Eur J Cancer. 2026. PMID: 42623835. doi:10.1016/j.ejca.2026.116992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。